Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia | Zendy

Diego Viasus | Zendy; Antonella F. Simonetti | Zendy; Carolina GarcíaVidal | Zendy; Jordí Niubó | Zendy; Jordi Dorca | Zendy; Jordi Carratalà | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia

Author(s) -

Diego Viasus,

Antonella F. Simonetti,

Carolina GarcíaVidal,

Jordí Niubó,

Jordi Dorca,

Jordi Carratalà

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw441

Subject(s) - medicine , pneumonia , pneumonia severity index , streptococcus pneumoniae , pneumococcal pneumonia , amoxicillin , antibiotics , community acquired pneumonia , sputum , retrospective cohort study , intensive care medicine , tuberculosis , microbiology and biotechnology , biology , pathology

Although antibiotic de-escalation is regarded as a measure that reduces selection pressure, adverse drug effects and costs, evidence supporting this practice in community-acquired pneumococcal pneumonia (CAPP) is lacking.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research